Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose

BioMetals

Volumn 25, Issue 5, 2012, Pages 961-969

  Conner, Todd A ^a   McQuade, Charles ^b   Olp, Jonathan ^b   Pai, Amy Barton ^c  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Cytokines; Hemodialysis; Inflammation; Iron sucrose; Oxygen radicals; Vitamin C

Indexed keywords

ASCORBIC ACID; CYTOKINE; HYDROGEN PEROXIDE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; IRON SACCHARATE; ISOPROSTANE DERIVATIVE; LIPID; REACTIVE OXYGEN METABOLITE; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; FLOW CYTOMETRY; HEMODIALYSIS PATIENT; HUMAN; IRON KINETICS; KIDNEY FAILURE; LIPID PEROXIDATION; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ASCORBIC ACID; CROSS-OVER STUDIES; CYTOKINES; ERYTHROPOIETIN; F2-ISOPROSTANES; FEMALE; FERRIC COMPOUNDS; GLUCARIC ACID; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; LIPID PEROXIDATION; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; SYSTEMS BIOLOGY;

EID: 84868139585     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-012-9562-6     Document Type: Article

References (42)

1. Attallah N, Osman-Malik Y, Frinak S et al (2006) Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 47(4):644-654
2. Berger TM, Polidori MC, Dabbagh A et al (1997) Antioxidant activity of vitamin C in iron-overloaded human plasma. J Biol Chem 272(25):15656-15660
3. Breuer W, Cabantchik ZI (2001) A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 299(2):194-202
4. Buettner GR, Jurkiewicz BA (1996) Catalytic metals, ascorbate and free radicals: Combinations to avoid. Radiat Res 145(5):532-541
5. Buettner GR, Moseley PL (1992) Ascorbate both activates and inactivates bleomycin by free radical generation. Biochemistry 31(40):9784-9788
6. Centers for Medicare and Medicaid Services (2008) Conditions for coverage, ESRD conditions final rule, April 15, 2008 http://www.cms.gov/ CFCsAndCoPs/13-ESRD.asp, cited 10 Feb 2012
7. Chan D, Irish A, Croft KD et al (2006) Effect of ascorbic acid supplementation on plasma isoprostanes in haemodialysis patients. Nephrol Dial Transplant 21(1):234-235
8. Chan D, Irish A, Dogra G (2005) Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. Nephrology (Carlton) 10(4):336-340
9. Chen WT, Lin YF, Yu FC et al (2003) Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: Influence of serum ferritin levels. Am J Kidney Dis 42(1):158-166
10. Cohen SD, Phillips TM, Khetpal P et al (2010) Cytokine patterns and survival in haemodialysis patients. Nephrol Dial Transplant 25(4):1239-1243
11. de Francisco AL, Stenvinkel P, Vaulont S (2009) Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus 2(Suppl 1):i18-i26
12. De Vriese AS, Borrey D, Mahieu E et al (2008) Oral vitamin C administration increases lipid peroxidation in hemodialysis patients. Nephron Clin Pract 108(1):c28-c34
13. Drueke T, Witko-Sarsat V, Massy Z et al (2002) Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:2212-2217
14. Eiselt J, Racek J, Opatrny K Jr et al (2006) The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C. Blood Purif 24(5-6):531-537
15. Esposito BP, Breuer VW, Slotki IN et al (2002) Labile iron in parenteral iron formulations and its potential for generating plasma non-transferrin bound iron (NTBI) in dialysis patients. Eur J Clin Inv 32:42-49
16. Fukunaga M, Makita N, Roberts LJ 2nd et al (1993) Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am J Physiol 264(6 Pt 1): C1619-C1624
17. Fumeron C, Nguyen-Khoa T, Saltiel C et al (2005) Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. Nephrol Dial Transplant 20(9):1874-1879
18. Gilbertson DT, Ebben JP, Foley RN et al (2008) Hemoglobin level variability: Associations with mortality. Clin J Am Soc Nephrol 3(1):133-138
19. Gniwotta C, Morrow JD, Roberts LJ 2nd et al (1997) Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 17(11):3236-3241
20. Hasegawa T, Bragg-Gresham JL, Pisoni RLet al (2010) Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney Int 79(3):340-346
21. KDOQI (2007) KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50(3):471-530
22. Keven K, Kutlay S, Nergizoglu G et al (2003) Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 41(6): 1233-1239
23. Locatelli F, Canaud B, Eckardt KU et al (2003) Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant 18(7):1272-1280
24. Milne GL, Sanchez SC, Musiek ES et al (2007) Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc 2(1):221-226
25. Morrow JD, Minton TA, Roberts LJ 2nd (1992) The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins 44(2):155-163
26. Ogata N, Yamamoto H, Kugiyama K et al (2000) Involvement of protein kinase C in superoxide anion-induced activation of nuclear factor-kappa B in human endothelial cells. Cardiovasc Res 45(2):513-521
27. Otaki Y, Nakanishi T, Hasuike Y, Moriguchi R, Nanami M, Hama Y, Izumi M, Takamitsu Y (2004) Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis. Am J Kidney Dis 43(6):1030-1039
28. Otero P, Viana M, Herrera E et al (1997) Antioxidant and prooxidant effects of ascorbic acid, dehydroascorbic acid and flavonoids on LDL submitted to different degrees of oxidation. Free Radic Res 27(6):619-626
29. Roberts MA, Hare DL, Ratnaike S et al (2006) Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 48(3):341-360
30. Rooyakkers TM, Stroes ESG, Kooistra MP et al (2002) Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32:9-16
31. Salahudeen AK, Oliver B, Bower JD et al (2001) Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 60(4):1525-1531
32. Shi X, Dong Z, Huang C, Ma W et al (1999) The role of hydroxyl radical as a messenger in the activation of nuclear transcription factor NF-kappaB. Mol Cell Biochem 194(1-2):63-70
33. Shi XF, Ding F, Zhu QY et al (2005) Use of ascorbate-rich dialysate to attenuate oxidative stress in maintenance hemodialysis patients. Ren Fail 27(2):213-219
34. Sirover WD, Siddiqui AA, Benz RL (2008) Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: A preliminary study. Ren Fail 30(9):884-889
35. Sonnweber T, Theurl I, Seifert M et al (2011) Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol Dial Transplant 26(3):977-987
36. Stefansson BV, Haraldsson B, Nilsson U (2008) Ascorbyl free radical reflects catalytically active iron after intravenous iron saccharate injection. Free Radic BiolMed 45(9):1302-1307
37. Stenvinkel P, Heimburger O, Paultre F et al (1999) Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55(5):1899-1911
38. Sturm B, Laggner H, Ternes N, Goldenberg H et al (2005) Intravenous iron preparations and ascorbic acid: Effects on chelatable and bioavailable iron. Kidney Int 67(3):1161-1170
39. Tarng DC, Hung SC, Huang TP (2004a) Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients. J Am Soc Nephrol 15(9):2486-2493
40. Tarng DC, Liu TY, Huang TP (2004b) Protective effect of vitamin C on 8-hydroxy-20-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients. Kidney Int 66(2):820-831
41. Weiss G, Gordeuk VR (2005) Benefits and risks of iron therapy for chronic anaemias. Eur J Clin Invest 35(Suppl 3):36-45
42. Zimmermann J, Herrlinger S, Pruy A et al (1999) Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55(2):648-658